Ruboxistaurin is a macrocyclic bisindolylmaleimide compound primarily investigated for its potential in treating diabetic microvascular complications, including diabetic retinopathy, peripheral neuropathy,… Read more









Ruboxistaurin is a macrocyclic bisindolylmaleimide compound primarily investigated for its potential in treating diabetic microvascular complications, including diabetic retinopathy, peripheral neuropathy, and macular oedema. As a selective protein kinase C beta inhibitor, it is studied for its ability to modulate pathways associated with hyperglycaemic damage in diabetic angiopathies. To support robust analytical research, this category provides high-quality reference standards of the Ruboxistaurin active pharmaceutical ingredient, alongside a comprehensive range of pharmacopeial and non-pharmacopeial impurities. Laboratories utilize these compounds, including stable isotope labelled analogues, to conduct rigorous impurity profiling, method validation, and quantitative analysis. By offering access to structurally identified metabolites and synthetic impurities, this collection enables precise monitoring of degradation products and metabolic pathways, ensuring strict quality control during the development and evaluation of this investigational therapeutic agent.